{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:02:08Z","timestamp":1780606928596,"version":"3.54.1"},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In clinical trials in populations with mild cognitive impairment, it is common for participants to initiate concurrent symptomatic medications for Alzheimer's disease after randomization to the experimental therapy. One strategy for addressing this occurrence is to exclude any observations that occur after the concurrent medication is initiated. The rationale for this approach is that these observations might reflect a symptomatic benefit of the concurrent medication that would adversely bias efficacy estimates for an effective experimental therapy. We interrogate the assumptions underlying such an approach by estimating the effect of newly prescribed concurrent medications in an observational study, the Alzheimer's Disease Neuroimaging Initiative.<\/jats:p>","DOI":"10.1002\/alz.12058","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T02:35:46Z","timestamp":1586399746000},"page":"797-803","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach"],"prefix":"10.1002","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6026-2238","authenticated-orcid":false,"given":"Michael C.","family":"Donohue","sequence":"first","affiliation":[{"name":"Alzheimer's Therapeutic Research Institute University of Southern California  San Diego California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Model","sequence":"additional","affiliation":[{"name":"F. Hoffmann \u2010 La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Delmar","sequence":"additional","affiliation":[{"name":"F. Hoffmann \u2010 La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Volye","sequence":"additional","affiliation":[{"name":"F. Hoffmann \u2010 La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu\u2010Seifert","sequence":"additional","affiliation":[{"name":"Eli Lilly  Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Rafii","sequence":"additional","affiliation":[{"name":"Alzheimer's Therapeutic Research Institute University of Southern California  San Diego California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Aisen","sequence":"additional","affiliation":[{"name":"Alzheimer's Therapeutic Research Institute University of Southern California  San Diego California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Alzheimer's Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"key":"e_1_2_5_2_1","unstructured":"Committee for Human Medicinal Products.ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials Step 2b. In:2017."},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0318-y"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-5-200803040-00009"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.11.005"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-015-0109-2"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000134664.80320.92"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050151"},{"key":"e_1_2_5_9_1","volume-title":"Draft guideline on the clinical investigation of medicines for the treatment of Alzheimer's disease and other dementia","author":"European Medicines Agency","year":"2016"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181cb3e25"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.12.2269"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.343"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0000000000000291"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181cb3e25"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199700112-00003"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.141.11.1356"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.11.2412-a"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1081\/BIP-100104194"},{"key":"e_1_2_5_20_1","volume-title":"R: A Language and Environment for Statistical Computing [computer program","year":"2018"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2010.03.006"},{"issue":"11","key":"e_1_2_5_22_1","first-page":"1430","article-title":"Safety and tolerability of the \u03b3\u2010secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease","volume":"69","author":"Coric V","year":"2012","journal-title":"JAMA Neurol"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Falz.12058","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.12058","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/alz.12058","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.12058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T21:17:43Z","timestamp":1759871863000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.12058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,8]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1002\/alz.12058"],"URL":"https:\/\/doi.org\/10.1002\/alz.12058","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,8]]},"assertion":[{"value":"2019-06-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}